Clinical News

In 2012, FDA achieved a milestone with the approval of 39 innovative drug therapies for populations in need.

After years of declining pipeline productivity, are we headed for a resurgence in new approvals? Here's a look at what's ahead for 2013.

A universal antidote for factor Xa inhibitors has entered phase 2 studies.

NSAIDs plus ACE inhibitors or ARBs can increase risk of kidney injury for patients taking diuretics.

Recent data were released on a long-term, open-label extension study evaluating clobazam for the adjunctive treatment of drop seizures.

Auto-programming infusion pumps reduces keystroke error and increases patient safety.

Healthcare professionals can now report errors and near-misses that are associated with vaccine administration.

The public is generally satisfied with cancer research progress over the past 20 years. However, they believe it takes too long for new cancer drugs to reach patients and that their countries invest too little in fighting cancer, according a global survey.

FDA approved mipomersen sodium (Kynamro, Genzyme and Isis Pharmaceuticals) once-a-week injection as an addition to lipid-lowering medications and diet to treat patients with a rare type of high cholesterol called homozygous familial hypercholesterolemia (HoFH).

An FDA advisory committee voted to move hydrocodone combination drugs from Schedule III into the more restrictive Schedule II category of controlled substances in late January.

The FDA recently approved teriflunomide for the treatment of patients with relapsing forms of multiple sclerosis.

According to a recent FDA safety announcement, varenicline may pose an increased risk of cardiovascular events.

Women who regularly took the analgesics ibuprofen or acetaminophen 2 or more days per week had an increased risk of hearing loss, according to a study.

You might know about medical foods, but they are making their way into ambulatory care and community pharmacy.

Patients with nonvalvular atrial fibrillation (NAVF) who also have diabetes experienced similar safety and efficacy with dabigatran relative to warfarin, in comparison without diabetes who have NVAF.

A look at how pharmacists can be involved with the "meaningful use" incentive program.

A new study indicates that adults are keeping their hypertension in check.

Metformin is one of the most important pharmacologic agents for diabetes, but patients need more to maintain optimal HbA1c levels.